Skip to main content

Table 1 Risk of recurrence and death according to socio-demographic and clinical characteristics

From: Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study

 

Patients

Disease-free survival

Overall survival

Events

(%)

HR (95% CI)

Events

(%)

HR (95% CI)

Gender

  Female

246

112

(45.5)

Ref

93

(37.8)

Ref

  Male

679

334

(49.2)

1.07 (0.85–1.35)

292

(43.0)

1.15 (0.89–1.48)

Age (years)

   < 60

195

70

(35.9)

Ref

52

(26.7)

Ref

  60–69

312

137

(43.9)

1.32 (0.98–1.77)

115

(36.9)

1.55 (1.11–2.17)

  70–79

281

143

(50.9)

1.77 (1.31–2.37)

132

(47.0)

2.28 (1.64–3.18)

   ≥ 80

137

96

(70.1)

2.99 (2.14–4.16)

86

(62.8)

3.82 (2.64–5.54)

Smoking habits

  Never

178

81

(45.5)

Ref

69

(38.8)

Ref

  Ever

655

333

(50.8)

1.33 (1.01–1.44)

279

(42.6)

1.35 (1.00–1.83)

  Missing

92

42

(46.6)

 

37

(40.2)

-

Drinking habits

  Never

453

219

(48.3)

Ref

183

(40.4)

Ref

  Ever

319

157

(49.2)

1.14 (0.90–1.43)

138

(43.3)

1.24 (0.97–1.59)

  Missing

153

70

(45.8)

 

64

(41.8)

-

Cancer site

  Oral cavity

413

199

(48.2)

1.31 (0.92–1.87)

175

(42.4)

1.69 (1.13–2.54)

  Oropharynx

93

43

(46.2)

Ref

32

(34.4)

Ref

  Hypopharynx

60

36

(60.0)

1.60 (0.99–2.56)

33

(55.0)

1.84 (1.10–3.10)

  Larynx

359

168

(46.8)

1.26 (0.87–1.81)

145

(40.4)

1.52 (1.00–2.30)

pT

  pT1

93

35

(37.6)

Ref

24

(25.8)

Ref

  pT2

320

145

(45.3)

1.31 (0.89–1.93)

122

(38.1)

1.71 (1.09–2.71)

  pT3

220

103

(46.8)

1.55 (1.03–2.34)

86

(39.1)

1.90 (1.18–3.08)

  pT4

282

158

(56.0)

1.83 (1.23–2.72)

148

(52.5)

2.52 (1.58–4.02)

  Missing

10

5

(50.0)

 

5

(50.0)

-

pN

  pN0

534

212

(39.7)

Ref

138

(32.5)

Ref

  pN1

121

68

(56.2)

1.67 (1.23–2.26)

59

(49.6)

1.72 (1.23–2.40)

  pN2-pN3

265

162

(61.1)

1.93 (1.42–2.64)

144

(56.1)

2.12 (1.51–2.97)

  Missing

5

4

(80.0)

 

3

(60.0)

-

Grading

  G1

93

37

(39.8)

Ref

32

(34.4)

Ref

  G2

469

211

(45.0)

1.30 (0.90–1.77)

180

(38.4)

1.21 (0.81–1.80)

  G3

303

166

(54.8)

1.43 (0.97–2.12)

144

(47.5)

1.32 (0.87–2.01)

  Missing

60

32

(53.3)

 

29

(48.3)

 

Surgical margins

  Negative

610

263

(43.1)

Ref

224

(36.7)

Ref

  Close/positive

243

140

(57.6)

1.31 (1.05–1.63)

120

(49.4)

1.27 (1.00–1.62)

  Missing

72

43

(59.7)

 

41

(56.9)

 

Extranodal extension

  Absent

765

336

(43.9)

Ref

283

(37.0)

Ref

  Present

160

110

(68.8)

1.34 (1.00–1.79)

102

(63.8)

1.41 (1.04–1.92)

Adjuvant (chemo) radiotherapy

  No

454

198

(43.6)

Ref

164

(36.1)

Ref

  Yes

463

241

(52.1)

0.76 (0.58–1.01)

214

(46.2)

0.81 (0.60–1.10)

  Missing

8

7

(87.5)

 

7

(87.5)

 
  1. Hazard ratio (HR) and corresponding 95% confidence intervals (CI) were estimated through Cox proportional hazard model, adjusting for study centre, gender, age, cancer site, pT, pN, surgical margins, extranodal extension, and adjuvant (chemo) radiotherapy